0001077183-24-000075.txt : 20240514 0001077183-24-000075.hdr.sgml : 20240514 20240514213920 ACCESSION NUMBER: 0001077183-24-000075 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20240511 FILED AS OF DATE: 20240514 DATE AS OF CHANGE: 20240514 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Smith Christopher M CENTRAL INDEX KEY: 0001436707 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-35756 FILM NUMBER: 24946821 MAIL ADDRESS: STREET 1: 125 CONSTITUTION DRIVE CITY: MENLO PARK STATE: CA ZIP: 94025 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: NEOGENOMICS INC CENTRAL INDEX KEY: 0001077183 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-TESTING LABORATORIES [8734] ORGANIZATION NAME: 08 Industrial Applications and Services IRS NUMBER: 742897368 STATE OF INCORPORATION: NV FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 9490 NEOGENOMICS WAY CITY: FORT MYERS STATE: FL ZIP: 33912 BUSINESS PHONE: 2397680600 MAIL ADDRESS: STREET 1: 9490 NEOGENOMICS WAY CITY: FORT MYERS STATE: FL ZIP: 33912 FORMER COMPANY: FORMER CONFORMED NAME: AMERICAN COMMUNICATIONS ENTERPRISES INC DATE OF NAME CHANGE: 19990120 4 1 wk-form4_1715737144.xml FORM 4 X0508 4 2024-05-11 0 0001077183 NEOGENOMICS INC NEO 0001436707 Smith Christopher M 9490 NEOGENOMICS WAY FORT MYERS FL 33912 0 1 0 0 Chief Executive Officer 0 Common Stock 2024-05-11 4 M 0 48063 0 A 650282 D Common Stock 2024-05-11 4 F 0 18913 14.86 D 631369 D Common Stock 2024-05-11 4 M 0 48063 0 A 679432 D Restricted Stock Unit 0 2024-05-11 4 M 0 48063 0 D Common Stock 48063 96127 D Stock Option (Right to Buy) 12.62 2029-08-15 Common Stock 694444 694444 D Stock Option (Right to Buy) 19.65 2030-05-11 Common Stock 269841 269841 D Performance Stock Unit 0 2026-05-11 Common Stock 144190 144190 D Stock Option (Right to Buy) 16.45 2034-02-23 Common Stock 287940 287940 D Restricted Stock Unit 0 Common Stock 172239 172239 D Performance Stock Unit 0 2027-02-23 Common Stock 172240 172240 D Each restricted stock unit is the economic equivalent of one share of NeoGenomics common stock and is converted into common stock upon vesting. Disposition of shares was in connection with the Issuer's withholding of common stock to satisfy tax withholding obligations related to the issuance of common stock upon release of restricted stock units. On May 11, 2023, Mr. Smith was granted 144,190 restricted stock units. These restricted stock units vest ratably over the first three anniversary dates of the grant date. Once vested, the shares of common stock are not subject to expiration. On August 15, 2022, Mr. Smith was granted 694,444 stock options. These options vest ratably over the first four anniversary dates of the grant date. On May 11, 2023, Mr. Smith was granted 269,841 stock options. These options vest ratably over the first three anniversary dates of the grant date. On May 11, 2023, Mr. Smith was granted 144,190 performance stock units representing the number of shares that may vest at target performance. The maximum number of shares that may vest pursuant to the performance criteria is 216,285. The number of performance stock units that may vest is based on the achievement of certain share growth goals based on the weighted average price of the Company's common stock over the 20-day trailing trading period at the applicable measurement dates, subject to continued service with the Company. On February 23, 2024, Mr. Smith was granted 287,940 stock options. These options vest ratably over the first three anniversary dates of the grant date. On February 23, 2024, Mr. Smith was granted 172,239 restricted stock units. These restricted stock units vest ratably over the first three anniversary dates of the grant date. On February 23, 2024, Mr. Smith was granted 172,240 performance stock units representing the number of shares that may vest at target performance. The maximum number of shares that may vest pursuant to the performance criteria is 258,360. 50% of the number of performance stock units that may vest is based on the achievements of certain share growth goals based on the weighted average price of the Company's common stock over the 20-day trailing trading period at the applicable measurement dates, subject to continued service with the Company. 50% of the number of performance stock units that may vest is based on the achievement of certain revenue growth goals based on the achievement of the cumulative fiscal year revenue goal at the applicable measurement amounts, subject to continued service with the Company. /s/ Ali Olivo, Attorney-in-Fact 2024-05-14